Dharmendra Bhakta
Medical · Phoenix, AZNPI 1780772319
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 376 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,413 and has fallen 53.9% since, to $1,114 in 2025. Among medical clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$954
- Biohaven Pharmaceuticals, Inc.$919
- Bayer$906
- Novo Nordisk$778
- GSK$715
- plus $4K from 28 others
What the payments were for
- Consulting fees$8008%
- Food & beverage$8,65791%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $1,028 |
| AbbVie | 54 | $954 |
| Biohaven Pharmaceuticals, Inc. | 4 | $919 |
| Bayer | 24 | $906 |
| Novo Nordisk | 30 | $778 |
| GSK | 43 | $715 |
| Lilly USA, LLC | 40 | $682 |
| Boehringer Ingelheim | 21 | $520 |
| Medtronic | 14 | $373 |
| Sanofi-aventis U.S. LLC | 9 | $365 |
| Amgen | 10 | $279 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $240 |
| Nestle Healthcare Nutrition Inc. | 10 | $203 |
| Dexcom, Inc. | 4 | $180 |
| Pfizer | 10 | $180 |
| Insulet Corporation | 4 | $161 |
| Abbott | 10 | $154 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $124 |
| Aimmune Therapeutics, Inc. | 5 | $109 |
| Merck | 6 | $98 |
| Boston Scientific | 3 | $76 |
| Amarin Pharma, Inc. | 5 | $70 |
| Sumitomo Pharma America, Inc. | 2 | $55 |
| Novartis | 3 | $52 |
| Astellas Pharma US Inc | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Exact Sciences | 2 | $29 |
| Eisai Inc. | 1 | $21 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Mannkind Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$925
- Kerendia$638
- BREZTRI$336
- MINIMED 780G$140
- Wegovy$125
- Repatha$125
- DEXCOM G6 TRANSMITTER$119
- INTERSTIM$113
- Omnipod$109
- MOUNJARO$105
- FASENRA$102
- FARXIGA$102
How this compares
$9,471 in reported general payments places this provider in the 90th percentile of 748 medical providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $66,808 |
| EliquisApixaban | 59 | $62,470 |
| JardianceEmpagliflozin | 64 | $49,452 |
| FarxigaDapagliflozin Propanediol | 42 | $42,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $37,661 |
| JanuviaSitagliptin Phosphate | 24 | $26,174 |
| MounjaroTirzepatide | 22 | $22,835 |
| XareltoRivaroxaban | 17 | $21,335 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $13,269 |
| TradjentaLinagliptin | 11 | $12,172 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,443 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,961 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $8,667 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $7,650 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $6,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $778 | $66,80844 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $715 | $64,86595 claims |
| PfizerEliquis | $180 | $62,47059 claims |
| Boehringer IngelheimJardiance, Tradjenta | $520 | $61,62475 claims |
| AstraZenecaFarxiga | $1,028 | $42,50942 claims |
| Lilly USA, LLCMounjaro, Humalog, Humulin 70-30 | $682 | $30,16656 claims |
| MerckJanuvia | $98 | $26,17424 claims |
| Johnson & JohnsonXarelto | $17 | $21,33517 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $365 | $15,55236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 748 medical providers in Arizona.
Other medical in Phoenix
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
- Jennifer KiserPhoenix$53K
- Lakeisha ColterPhoenix$48K
- Amy IngersollPhoenix$42K
- Ty NielsonPhoenix$18K
- Brittany SilvermanPhoenix$16K
- John RimerPhoenix$15K
- Rana AoufePhoenix$14K
- Adam SchwartzPhoenix$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.